June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The Quebec Corneal Cell Bank: Update on Culture Success of Pathologic Human Corneal Endothelial Cells (2009-2012)
Author Affiliations & Notes
  • Mathieu Theriault
    LOEX/CUO - Recherche, Centre de recherche du CHU, Quebec, QC, Canada
  • Olivier Roy
    LOEX/CUO - Recherche, Centre de recherche du CHU, Quebec, QC, Canada
  • Olivier Rochette-Drouin
    LOEX/CUO - Recherche, Centre de recherche du CHU, Quebec, QC, Canada
  • Marie-Claude Perron
    Centre de recherche HMR, Montréal, QC, Canada
  • Isabelle Brunette
    Centre de recherche HMR, Montréal, QC, Canada
    Ophtalmologie, Université de Montréal, Montréal, QC, Canada
  • Stephanie Proulx
    LOEX/CUO - Recherche, Centre de recherche du CHU, Quebec, QC, Canada
    Ophtalmologie, Université Laval, Quebec, QC, Canada
  • Footnotes
    Commercial Relationships Mathieu Theriault, None; Olivier Roy, None; Olivier Rochette-Drouin, None; Marie-Claude Perron, None; Isabelle Brunette, None; Stephanie Proulx, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1664. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mathieu Theriault, Olivier Roy, Olivier Rochette-Drouin, Marie-Claude Perron, Isabelle Brunette, Stephanie Proulx; The Quebec Corneal Cell Bank: Update on Culture Success of Pathologic Human Corneal Endothelial Cells (2009-2012). Invest. Ophthalmol. Vis. Sci. 2013;54(15):1664.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The purpose of this study was to assess the feasibility of initiating primary cultures of corneal endothelial cells from patients suffering from various corneal diseases. We also evaluated which conditions yielded the best results for culture.

Methods: Consenting patients undergoing penetrating keratoplasty or Descemet’s stripping automated endothelial keratoplasty were enrolled in this study. The cornea (or Descemet’s membrane), removed at the time of surgery, was sent to the laboratory. Upon receipt, specimens were photographed, endothelial cells were isolated and cultured, and Descemet’s membranes were fixed in 3.7% formaldehyde for histology. Data collected included diagnosis, age and sex of the donor, time spent in Optisol, culture success and number of cells obtained after a primary culture. Control healthy Eye Bank corneas were processed in a similar manner.

Results: A total of 194 specimens were obtained between August 2009 and November 2012. Pathologies included Fuchs corneal endothelial dystrophy (FECD; n=93), pseudophakic bullous keratoplathy (PBK; n=33), FECD+PBK (n=4) and other corneal disorders (n=64). Overall, 56 of the 194 diseased specimens (FECD n=37; PBK n=3; FECD+PBK n=2; other n=14) and all of the 29 healthy corneas successfully initiated an endothelial cell culture. Among the diseased specimens, the mean(±SD) donor age was 66.5 ±11.9 years for successful cultures and 68.9 ±15.2 years for the unsuccessful cultures. Time spent in Optisol was 2.7 ±1.2 and 3.2 ±2.6 days for successful and unsuccessful cultures, respectively. The diseased specimens yielded 120 000 ±86 000 cells and the healthy corneas 122 000 ±55 000 cells.

Conclusions: This study shows that successful corneal endothelial cell culture can be generated despite various corneal diseases. FECD allowed the highest success rate. Once culture was initiated, a similar number of cells was obtained from FECD, BPK and healthy specimens. Patient sex and age, and the time spent by the specimen in Optisol did not influence success rate. The Quebec Corneal Cell Bank will become a useful tool for the study of various corneal endotheliopathies.

Keywords: 481 cornea: endothelium • 638 pathology: human  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×